--- title: "Rapidly growing tech startup OpenEvidence revolutionizes patient care in US" url: https://noti.group/rapidly-growing-tech-startup-openevidence-revolutionizes-patient-care/ language: en publisher: "Noti Group" section: "Technology" published: 2026-10-21T15:14:07.000Z updated: 2026-10-21T19:40:47.222Z id: 92bddc77-f3d8-4f45-adb0-6f2e6d3488be source: "Ars Technica https://arstechnica.com/ai/2026/10/the-15-billion-ad-powered-ai-startup-your-doctor-may-already-be-using/" attribution: "Link to https://noti.group/rapidly-growing-tech-startup-openevidence-revolutionizes-patient-care/ and name Noti Group when you quote or summarize this story." --- # Rapidly growing tech startup OpenEvidence revolutionizes patient care in US OpenEvidence's AI-powered search engine has been used over 42 million times last month, with many physicians relying on it to diagnose and treat patients. A rapidly growing tech startup is revolutionizing patient care in the US, with nearly two-thirds of American doctors turning to an AI-powered search engine to inform their decisions. The platform, developed by Miami-based OpenEvidence, has been used over 42 million times last month alone, with many physicians relying on it to diagnose and treat patients. OpenEvidence's chatbot allows doctors to quickly scour medical journals and clinical guidelines, a task that can be time-consuming and complex. Founded by serial entrepreneur Daniel Nadler in 2022, the company has grown largely through word of mouth, with few tools in this sector achieving similar traction. The platform's success has been driven in part by its ease of use and ability to alleviate workloads for medical professionals. According to interviews with eight senior physicians, OpenEvidence has won praise for helping doctors streamline their workflow and make more informed decisions. However, the company's growing influence is also sparking controversy. As more doctors rely on AI tools like OpenEvidence to inform their treatments, concerns are being raised about the accuracy of its results. Researchers are warning that over-reliance on these platforms could compromise patient care. OpenEvidence now boasts a valuation of $15 billion, a staggering figure that reflects its rapid growth and widespread adoption in the medical community. But with the likes of OpenAI and Anthropic also making inroads into this space, the company's dominance may be short-lived. In a remarkable display of growth, OpenEvidence has secured nearly $1 billion in investment over the past 18 months from prominent backers such as Andreessen Horowitz and Blackstone. The company's latest funding round, which took place in September, valued it at an impressive $15 billion. This influx of capital will likely fuel further expansion for the startup, which is already generating significant revenue through its ad-powered model. OpenEvidence has reportedly booked $100 million in "ad buys" for this year, with projections indicating that it will generate between $400 million and $500 million through ads by the end of 2026. The company's success can be attributed to its early mover advantage in a market for medical software that was initially slow to adopt generative AI models. For instance, Dutch IT group Wolters Kluwer released an AI version of its UpToDate tool only recently, nearly two years after OpenEvidence entered the market. OpenEvidence's tool has been integrated into the electronic health records of several prominent hospitals and clinics in New York, including Mount Sinai Health System and Memorial Sloan Kettering Cancer Center. This integration was made possible by the widespread adoption of OpenEvidence among clinicians at these institutions, who were already using the tool as an independent resource. According to Paul Testa, chief health informatics officer at NYU Langone, the hospital system decided to formalize its relationship with OpenEvidence after observing this trend. The hospital's decision was driven by a desire to ensure that clinicians could get the most out of AI tools like OpenEvidence while also using them securely within their care process. Testa emphasized the importance of integrating OpenEvidence in a way that maximized its clinical value and minimized security risks. As OpenEvidence continues to expand, it is exploring new applications for its technology beyond healthcare, including ambient documentation, the use of AI-powered note-taking during patient interactions. This development reflects the company's goal of leveraging its popularity among physicians to establish itself as a leader in multiple domains. The company's expansion into literature-based drug discovery is a significant development, aiming to unlock new insights from vast amounts of scientific data. By leveraging this approach, Anthropic aims to create value that far surpasses any potential revenue generated through advertising or partnerships with hospitals. To support its clinical work, the company has welcomed Alexander Tarashansky, creator of Claude Science, an Anthropic platform designed for research scientists. This addition brings valuable expertise and experience in supporting research efforts, potentially enhancing the company's capabilities in this area. Anthropic faces competition from other frontier AI companies, including OpenAI, which has developed ChatGPT for healthcare applications. The latter has also partnered with OpenEvidence to bring its tools to 100 low- and middle-income countries, increasing the competitive landscape for Anthropic. A recent analysis of OpenEvidence's effectiveness has yielded mixed results, with a study by the Mayo Clinic finding that it provided accurate recommendations in patient case studies but had limited impact on treatment decisions. Research published in Nature has highlighted limitations in OpenEvidence's performance on clinical benchmarks compared to general-purpose AI models like Google's Gemini and OpenAI's GPT. Concerns have been raised by medical professionals about the over-reliance on AI systems such as OpenEvidence without proper understanding of underlying conditions and treatment options. This is particularly worrying for junior doctors who may not possess the necessary expertise to evaluate AI recommendations effectively. The use of AI tools in clinical settings requires careful consideration, and more research is needed to establish their reliability and optimal implementation strategies. --- Source: [Ars Technica](https://arstechnica.com/ai/2026/10/the-15-billion-ad-powered-ai-startup-your-doctor-may-already-be-using/) Published by Noti Group: https://noti.group/rapidly-growing-tech-startup-openevidence-revolutionizes-patient-care/